Erste Asset Management GmbH reduced its position in Zoetis Inc. (NYSE:ZTS – Free Report) by 93.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,581 shares of the company’s stock after selling 69,963 shares during the quarter. Erste Asset Management GmbH’s holdings in Zoetis were worth $577,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. RFG Advisory LLC lifted its position in Zoetis by 4.9% in the fourth quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares during the period. YANKCOM Partnership lifted its position in Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock worth $302,000 after purchasing an additional 81 shares during the period. Beese Fulmer Investment Management Inc. lifted its position in Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock worth $537,000 after purchasing an additional 85 shares during the period. Quest 10 Wealth Builders Inc. lifted its holdings in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after acquiring an additional 86 shares during the period. Finally, Financial Engines Advisors L.L.C. lifted its holdings in shares of Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock valued at $299,000 after acquiring an additional 87 shares during the period. 92.80% of the stock is owned by institutional investors.
Key Headlines Impacting Zoetis
Here are the key news stories impacting Zoetis this week:
- Negative Sentiment: Several law firms, including Rosen, Robbins Geller, Bernstein Liebhard, Levi & Korsinsky, Schall, Pomerantz, and others, have announced or promoted securities-class-action claims against Zoetis, increasing headline risk and potentially signaling investor concern over prior disclosures. Article Title
- Negative Sentiment: The lawsuits specifically reference alleged share-price damage and loss recovery for purchasers during the class period, which can weigh on sentiment by raising the prospect of legal costs, management distraction, and possible settlements. Article Title
- Neutral Sentiment: Bank of America Securities reportedly reiterated a Hold rating on Zoetis, suggesting analysts are cautious but not turning decisively bearish. Article Title
Zoetis Stock Performance
Zoetis (NYSE:ZTS – Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The business had revenue of $2.26 billion during the quarter, compared to analyst estimates of $2.30 billion. During the same quarter last year, the business posted $1.48 earnings per share. The business’s quarterly revenue was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, equities research analysts predict that Zoetis Inc. will post 6.88 EPS for the current fiscal year.
Zoetis Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.6%. Zoetis’s dividend payout ratio (DPR) is 35.16%.
Analysts Set New Price Targets
A number of research analysts have issued reports on the company. UBS Group cut their price objective on Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a report on Friday, May 8th. Morgan Stanley reissued an “overweight” rating and set a $115.00 price objective on shares of Zoetis in a report on Friday, May 15th. Wall Street Zen cut Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, March 27th. Finally, BTIG Research reissued a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $133.92.
Read Our Latest Research Report on ZTS
Insider Activity
In other Zoetis news, Director Paul Bisaro bought 2,000 shares of the stock in a transaction dated Wednesday, May 13th. The stock was bought at an average cost of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the purchase, the director owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Frank A. Damelio bought 6,650 shares of the stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This represents a 44.91% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders acquired 11,650 shares of company stock worth $886,384. 0.22% of the stock is owned by corporate insiders.
Zoetis Company Profile
Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.
Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.
Featured Articles
- Five stocks we like better than Zoetis
- Everpure: AI Storage Uncertainty Overshadows Breakneck Growth
- This Tech ETF Is Beating QQQ—and Canada May Be Part of the Reason
- Intel Is the Market’s Most Mispriced AI Hedge
- The Biggest Opportunity From SpaceX’s IPO May Surprise You
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.
